Evidence has emerged for a role of vitamin D in the development of breast cancer, and there is some suggestion that its antiproliferative effect is greater in hormone-receptor-positive cells. Few epidemiologic studies have considered the association between vitamin D and hormone-receptor-defined breast cancer, and the results are conflicting. Considering 759 cases and 1,135 controls from a case-control study (Ontario, Canada, 2003 -2005 , the authors examined the association between vitamin D intake at specific ages and combined estrogen-receptor-(ER) and progesterone-receptor-(PR) defined breast cancer. While increased intake of vitamin D (from the sun and diet) was most consistently associated with a significantly reduced risk of ERþ/PRþ tumors (e.g., odds ratio ¼ 0.76, 95% confidence interval: 0.59, 0.97 for use of cod liver oil during adolescence), comparable nonsignificant associations were found for receptor-negative (ERÀ/PRÀ) (odds ratio ¼ 0. Studies supporting a role of vitamin D in the prevention of several cancers, including breast cancer, have recently emerged (1-3). Vitamin D is primarily obtained through exposure of the skin surface to ultraviolet B radiation, but small amounts can be ingested through limited dietary sources (e.g., fortified milk, fatty fish) and supplements (4-6). The biologic mechanism by which vitamin D might prevent breast cancer has been summarized previously (5-11). The active form of vitamin D (1,25-dihydroxyvitamin D (1,25(OH) 2 D)) can inhibit cellular proliferation and induce differentiation and apoptosis in normal and cancerous breast cells (7-10). In carcinogen-exposed rats, 1,25(OH) 2 D or its analogues have been shown to reduce the incidence and size of tumors and delay mammary tumor development (11). 25(OH)D-1-a hydroxylase, the enzyme that converts 25-hydroxyvitamin D (25(OH)D) to its active form, and the vitamin D receptor, through which 1,25(OH) 2 D mediates its effects, are present in normal and cancerous breast epithelia (7-10).
. Nonetheless, in some studies (13, 15, 16) , receptor status was unavailable for a significant proportion of cases (30%-50%); in others, the total number of cases with a negative ER and PR status was very small (n < 100) (14) , thereby limiting interpretation of the overall findings. Furthermore, these studies did not assess sun exposure history and hormone receptor status.
In a recently completed, population-based case-control study, we found a strong inverse association between several reported vitamin D exposures from the sun (e.g., odds ratio ¼ 0.65, 95% confidence interval: 050, 0.85 for the highest quartile of outdoor activities vs. the lowest) and diet (e.g., odds ratio ¼ 0.76, 95% confidence interval: 0.62, 0.92 for cod liver oil use) during adolescence and overall breast cancer risk (17) . Some evidence was observed for exposures during early adulthood, with little evidence of a relation between perimenopausal exposures and breast cancer (17) . To add to the limited literature regarding the relation between vitamin D and hormone-receptor-defined breast cancer, we examined whether the associations observed between reported vitamin D exposures from the sun and diet during these 3 time periods and subsequent breast cancer varied by joint ER and PR status. In contrast to previous studies, receptor status was available for approximately 80% of cases.
MATERIALS AND METHODS
Details of the study design and population have previously been described (17) . This study was approved by the local institution's research ethics board. We conducted a population-based-case-control study in the province of Ontario, Canada. Cases were identified through the Ontario Cancer Registry and were randomly sampled from women aged less than 70 years with incident, pathology confirmed, first primary invasive breast cancer diagnosed between July 1, 2003, and August 31, 2004 . Of the 1,610 eligible cases identified, physician permission to contact 1,350 (84%) was obtained. Of the 1,350 women we attempted to contact, 972 (72%) completed a telephone interview.
For the majority of recruited cases (n ¼ 665, 68%), ER and PR status (positive/negative) was available from pathology reports obtained from the Ontario Cancer Registry. However, for the remaining cases (n ¼ 307, 32%), hormone receptor status was unavailable. For these cases, consent was obtained from 249 women (81%) authorizing release of pathology reports from the medical records departments of hospitals where surgery had been performed. Pathology reports were received for 224 (90%) of these women, 129 (58%) of which contained information on ER and PR status. Immunohistochemical assays were the predominant method used to determine hormone receptor status. In total, ER status was available for 784 cases (81%), PR status was available for 763 cases (78%), and joint ER and PR status (ERþ/PRþ, ERþ/PRÀ, ERÀ/PRþ, ERÀ/PRÀ) was available for 762 cases (78%). A status of ''borderline'' was considered unknown. Because the number of ERÀ/PRþ cases was small (n ¼ 3), this category was omitted from the analysis, resulting in a total of 759 cases.
Population controls were women who reported no prior breast cancer and were living in the province of Ontario. Controls were identified through randomly selected residential telephone number lists and were frequency matched to cases by 5-year age group. Of the 1,974 telephone numbers for which an eligible control was identified, 1,376 (70%) potential controls agreed to participate; of these women, 1,135 (82%) completed the telephone interview.
During the interview, cases and controls were asked to recall their sun exposure history and their dietary and supplemental vitamin D intake with respect to 3 age groups: 10-19, 20-29, and 45-54 years (17) . These age groups were chosen to capture exposures during breast development in adolescence and early adulthood and breast involution occurring around the time of menopause. Studies have shown that some risk factors (e.g., smoking, ionizing radiation, phytoestrogen intake) may have a greater influence on subsequent breast cancer risk when exposures occur during periods of rapid tissue growth and change (18) (19) (20) .
Sun-exposure-related variables included number of days per week on which at least half an hour was spent outside (<7 vs. 7), total number of outdoor activity episodes of at least half an hour during the summer (quartiles based on the distribution among controls), ever having a job involving at least half an hour of outdoor work per day (yes/no), usually keeping arms and legs covered when outside in the summer (no, partial coverage, yes), skin usually burned or darkened in the summer (yes/no), usually used sunscreen in the summer (yes/no), ever took a trip to a summer climate in the winter (yes/no), and ever used a sunlamp or sun (tanning) bed (yes/no). In Canada, major food sources of vitamin D are limited, and dietary intake variables included number of glasses of milk per week (none, <5, 5-9, !10), number of servings of salmon/tuna (canned or fresh) per week (none, <1, 1, >1), ever took cod liver oil at least once per week (yes/no), and use of vitamin supplements (none, supplements without vitamin D, vitamin D or multivitamins).
Unordered polytomous logistic regression was used to generate odds ratios and their 95% confidence intervals for variables related to vitamin D (from the sun and diet) for each joint hormone receptor subgroup (ERþ/PRþ, ERþ/PRÀ, ERÀ/PRÀ). In this model, the dependent variable (receptor-status-defined breast cancer) was treated as a polytomous nominal variable, and the logit estimator always compared each joint-receptor-status-defined case with the common control group, enabling simultaneous estimation of subgroup-specific risk parameters. Significant differences in odds ratios among the 3 case subgroups for vitamin-D-related exposures were tested by using the Wald statistic P value, which is calculated based on differences in parameter estimates and their covariances from the polytomous logistic regression model (21) .
All models included age (continuous), defined as age at diagnosis for cases and age at interview for controls, and all fully adjusted models included education (high school or less, some university or technical school, university graduate) and ethnicity (northern European, mixed or other European, non-European). We considered the following known breast cancer risk factors as potential confounders: age at menarche ( 11, 12, 13 , !14 years), menopausal status (premenopausal, postmenopausal, unknown), menopausal status with age at menopause (premenopausal, unknown, and age at menopause in 4 categories), hormone therapy ever use (no/yes), age at first birth (<20, 20-24, 25-29, !30 years; nulliparous), parity (none, 1, 2, !3 births), ever breastfed (no/yes), first-degree family history of breast cancer (no/yes), body mass index (weight (kg)/height (m) 2 ) 2 years prior to the reference date ( 20.0, 20.1-24.9, 25.0-29.9, !30), body mass index at age 18 years ( 20.0, 20.1-24.9, !25.0), and alcohol use (none, <7 drinks/week, !7 drinks/week). In this study, age at menarche, age at first birth, ever breastfed, and first-degree family history were all significantly associated with risk of breast cancer and were therefore also included in the fully adjusted models.
Tests of linear trend were performed by using polytomous logistic regression. Stratified analyses according to menopausal status (premenopausal and postmenopausal) were also executed. Differences in vitamin-D-related exposures between women with known and unknown receptor status were examined by using a chi-square analysis. All analyses were conducted with SAS version 9.1 software (Stata Corporation, College Station, Texas). All tests were 2 sided, with P < 0.05 as the criterion for significance. Table 1 describes cases and controls according to demographic and other characteristics. Among the 759 cases Table continues 918 Blackmore et al.
RESULTS
considered in the analysis, 450 (59%) were ERþ/PRþ, 110 (14%) were ERþ/PRÀ, and 199 (26%) were ERÀ/PRÀ. Cases with ERþ/PRÀ tumors were slightly older and more likely to be postmenopausal, be nulliparous, and to have never breastfed. A higher proportion of women with ERþ/PRÀ and ERÀ/PRÀ tumors were of non-European heritage. Women with ERþ/PRþ tumors were slightly more likely to report a first-degree family history of breast cancer.
We observed few and inconsistent differences in risk estimates regarding vitamin-D-related exposure variables (from diet and the sun) between subsets of patients defined by joint ER and PR status (Tables 2 and 3 ). Between the ages of 10 and 19 years, ever having taken cod liver oil was associated with a significantly reduced risk of ERþ/PRþ tumors, although the estimates in ERþ/PRÀ and ERÀ/PRÀ subgroups were comparable. The negative association for increasing milk consumption in adolescence and early adulthood was significantly different between all 3 tumor subgroups (P ¼ 0.002 and P ¼ 0.03, respectively), with a stronger reduced risk for ERþ/PRþ tumors (P for linear trend ¼ 0.003 and P for linear trend ¼ 0.03, respectively). However, significant trends were observed for ERÀ/PRÀ tumors for both age groups (P ¼ 0.02 Abbreviations: CI, confidence interval; ER, estrogen receptor; OR, odds ratio; PR, progesterone receptor. a The Wald statistic P value indicates the statistical significance of differences in odds ratios for a given exposure among the 3 case subgroups. It was calculated based on differences in parameter estimates and their covariances from the fully adjusted polytomous regression model. b Odds ratios were adjusted for reference age, ethnicity, family history in first-degree relatives, ever breastfed, education, age at menarche, and age at first birth. Table continues 920 Blackmore et al. Abbreviations: CI, confidence interval; ER, estrogen receptor; OR, odds ratio; PR, progesterone receptor. a The Wald statistic P value indicates the statistical significance of differences in odds ratios for a given exposure among the 3 case subgroups. It was calculated based on differences in parameter estimates and their covariances from the fully adjusted polytomous regression model. b Odds ratios were adjusted for reference age, ethnicity, family history in first-degree relatives, ever breastfed, education, age at menarche, and age at first birth.
c Number of days outside for at least half an hour during the summer (June, July, August). d Number of outdoor activity episodes derived from reported outdoor activities performed for at least 30 minutes between 9 AM and 5 PM at least once per month during June, July, and August along with frequency (days per week or month) and duration (number of years).
Vitamin D and Receptor-Defined Breast Cancer 921 and P ¼ 0.01, respectively). Between the ages of 20 and 29 years, increased milk consumption also showed similar inverse associations for ERþ/PRÀ tumors, and the P for trend approached significance (P ¼ 0.05). The odds ratios for general vitamin supplement use (vitamin D/multivitamins and other) between the ages of 10 and 19 and 20 and 29 years were significantly different between tumor subgroups (P ¼ 0.002 and P ¼ 0.006, respectively), being more significantly associated with a reduced risk of ERþ/PRþ tumors. Table 3 shows the association between sun exposure variables and breast cancer by joint ER and PR status of the tumor. Between the ages of 10 and 19 years, the inverse association with increasing frequency of outdoor activities was more pronounced among women with ERþ/PRþ and ERþ/PRÀ tumors, and the P for trend was significant for both subgroups (P ¼ 0.007 and P ¼ 0.04, respectively); however, a significant difference in odds ratios among the 3 tumor subtypes was not observed (P ¼ 0.12). A similar pattern was observed for increasing frequency of outdoor activities between the ages of 20 and 29 years. The reduced risk of breast cancer for women who reported ever working outdoors between the ages of 10 and 19 years was different across tumor subtypes (P ¼ 0.003), showing a stronger reduced risk associated with both ERþ/PRÀ and ERÀ/PRÀ tumors.
Between the ages of 10 and 19 and 20 and 29 years, a significant positive association and a significant P for trend were observed between degree of limb coverage and ERþ/ PRþ breast cancers (P for trend ¼ 0.001 for both). Weaker positive associations were observed for ERþ/PRÀ and ERÀ/PRÀ tumors, although the difference in estimates among the 3 tumor subgroups approached significance (age 10-19 years, P ¼ 0.06; age 20-29 years, P ¼ 0.05). Women whose skin did not darken or burn in adolescence had a significantly increased risk of ERþ/PRþ tumors, although the odds ratio was not significantly different from that for the other tumor subtypes (P ¼ 0.13).
Examination of vitamin-D-related exposures (from the sun and diet) among women with and without information on ER and PR status revealed no significant differences (data not shown). We further observed no significant differences in the results between premenopausal and postmenopausal women or between women who used and did not use hormone therapy (ever vs. never users) (data not shown). Results for ERþ/PRþ tumors were similar to those for ERþ and PRþ cases alone, and those for ERÀ/PRÀ tumors were similar to results for ERÀ and PRÀ cases alone (data not shown).
DISCUSSION
In this study, vitamin D from dietary intake and sun exposure during adolescence and early adulthood was most consistently associated with a reduced risk of ERþ/PRþ tumors, possibly because this subgroup was the largest. However, some significant and nonsignificant inverse associations were also observed for receptor-negative (ERÀ/PRÀ) and/or mixed (ERþ/PRÀ) tumors.
The epidemiologic evidence to date regarding vitamin D intake and hormone-receptor-defined breast cancer is limited and conflicting (13) (14) (15) (16) . In the Cancer Prevention Study II Nutrition Cohort, a stronger inverse relation was observed between increased dietary vitamin D intake (>300 IU/day vs. 100 IU/day) and ERþ postmenopausal breast cancer; however, for total vitamin D (diet plus supplements), no association was found with increasing intake (13) . Results were similar when combined ER/PR status was considered (i.e., ERþ/PRþ was similar to ERþ alone, and ERÀ/PRÀ was similar to ERÀ). Conversely, in the Iowa Women's Health Study, for postmenopausal women, a stronger, nonsignificant inverse association was observed for the highest versus lowest groups of total vitamin D intake (!800 IU/day vs. <400 IU/day) among women with ERÀ/PRÀ tumors (15) . In the Women's Health Study, higher intake of total vitamin D (in quintiles) was associated with a reduced risk of developing ERþ or PRþ tumors among premenopausal women only (14) . Janowsky et al. (16) found that the risk associated with levels of 1,25(OH) 2 D in whole blood below the median value was higher for receptor-positive (ER and/ or PR present) than receptor-negative (neither receptor present) breast cancers.
In contrast to previous studies, we considered vitamin D intake from specific dietary sources separately in our analysis. Milk contributes about 100 IU of vitamin D per glass (22) , and milk drinking during adolescence and early adulthood did contribute more strongly to a reduced risk of ERþ/ PRþ tumors, although weaker inverse associations were observed for ERÀ/PRÀ tumors. Salmon and tuna provide approximately 360 IU per serving and 200 IU per serving (Office of Dietary Supplements, National Institutes of Health (http://ods.od.nih.gov/factsheets/vitamind.asp)), respectively; however, we did not observe an association with any tumor subgroup, likely because these fish were rarely eaten more than once a week. We only crudely assessed vitamin D supplement use and found that vitamin use in general during adolescence and early adulthood was associated with a reduced risk of ERþ/PRþ tumors. Since we examined exposures earlier in life, we did, however, consider cod liver oil, a traditional source of vitamin D particularly for children, which provides about 400 IU per teaspoon (5 mL) (4). Although we observed a significantly reduced risk of ERþ/PRþ tumors when cod liver oil was taken earlier in life, similar inverse associations were found for the other 2 tumor subgroups. Previous studies likely did not ask about cod liver oil because they focused on dietary intake later in life (i.e., age 45 years or older) (13) (14) (15) . The original Nurses' Health Study and Nurses' Health Study II examined dietary intake of vitamin D during high school, but neither considered hormone receptor status of the tumor and did not consider cod liver oil (23, 24) .
Sun exposure is a major source of vitamin D, and a maximal dose (~20,000 IU) can be obtained from a slight reddening of the skin (1 minimal erythemal dose) in less than 0.5 hours for light-colored skin, although a longer time is required for darker skin (25) . In contrast to most other studies, we asked about summer sun exposure behaviors since, at northern latitudes, vitamin D is produced at this time only (5, 6) . Similar to our dietary findings, greater sun exposure earlier in life (i.e., outdoor activities/job, degree of limb coverage, whether skin burned/darkened) was more consistently associated with a reduced risk of ERþ/PRþ tumors, but comparable significant and nonsignificant estimates were found for women with ERÀ/PRÀ and/or ERþ/ PRÀ tumors. Previous studies that did not consider sun exposure may have missed associations between vitamin D and hormone-receptor-defined subgroups.
Two possible reasons could explain the conflicting evidence reported in the present and earlier studies. The first is the possibility of inadequate statistical power due to the small number of cases within strata defined by hormone receptor status, especially among receptor-negative tumors, which constitute a minority of breast cancers diagnosed (20) . Of all studies, those by McCullough et al. (13) and Robien et al. (15) included the largest number of receptornegative cases (n ¼ 227 and n ¼ 274, respectively); however, in the first study, ER status was available for only 53% of the population, whereas, in the second study, joint receptor status was available for 68% of the population. In the Women's Health Study, the number of cases with ER-and PR-tumors was even smaller, particularly among premenopausal women (n ¼ 59 and n ¼ 74, respectively), but the overall proportion of cases with known ER and PR status was high (95%) (14) . The study by Janowsky et al. (16) had both a small proportion of cases whose receptor status was known (56%) and a very small number of receptor-negative cases (n ¼ 21). In our study, receptor status was available for 80% of cases, and we had a slightly larger number of ERÀ and PR-cases (ERÀ, n ¼ 206; PRÀ, n ¼ 309; and ERÀ/ PRÀ, n ¼ 199) compared with some studies (14, 16) .
Second, although an inverse relation between vitamin D and breast cancer is evident, vitamin D may not affect the risk of developing a specific type of hormonally defined breast cancer. Some data support the concept that the antiproliferative and antitumor effects of vitamin D and its analogues (e.g., EB1089) on estrogen-responsive breast cancer cells (ERþ) are mediated via disruption of estrogen mitogenic and survival signals (8, 9) . However, more recent studies of intracellular signaling in ER-breast cancer cell lines with a functional vitamin D receptor (e.g., SUM-159PT) have shown that vitamin D and its analogues can inhibit proliferation and induce growth arrest and apoptosis in these cells as well (26, 27) . Hence, even though the estrogen signaling pathway is disrupted, sensitivity to the effects of vitamin D is maintained during the progression from an estrogen-dependent to an estrogen-independent state via the presence of the vitamin D receptor (26, 27) .
This study has several strengths and limitations worth noting. Strengths include the consideration of potential markers of vitamin D synthesis from sun exposure as well as exposures earlier in life and risk of hormone-receptordefined breast cancer. Joint ER and PR status was also available for 80% of cases, and we were able to examine associations among women with ERþ/PRÀ tumors in addition to receptor-positive and -negative cases. However, the number of ERÀ/PRÀ and ERþ/PRÀ tumors was still relatively small, although significant associations were observed in a few cases. Some findings may also be subject to chance because of the many analyses performed. Accuracy of recall, especially for early-life exposures, is a concern in any case-control study, although several studies have found evidence that sun exposure, both recent and in childhood and adolescence, could be recalled reasonably consistently (28) . Recent studies, including our own, comparing responses to vitamin-D-related questions (from the sun and/ or diet) to circulating levels of 25(OH)D showed significant associations between recent exposures and 25(OH)D levels (28, 29) . Biased recall between cases and controls is also a concern, although differential recall between cases with differing hormone-defined breast cancer is unlikely. At the time our study was conducted, there was little media attention regarding a potential relation between vitamin D or sun exposure and breast cancer (17) .
To conclude, we previously reported an inverse relation between increased vitamin D intake from the sun and diet, especially during adolescence and early adulthood, and overall breast cancer risk (17) . In the present study, results suggest that vitamin D intake early in life influences breast cancer risk regardless of ER/PR receptor status. Although significant estimates were most consistently found for women with receptor-positive cancers (ERþ/PRþ), the largest subgroup, similar nonsignificant and significant associations were at times observed for receptor-negative and mixed tumors. Future studies should include a larger number of women with receptor-negative cancers.
